Gary Exelbert

SVP, Group Management Director @Fcb Health New York

New York, NY, US

Pitched and currently oversee the consumer engagement for FILSPARI (Travere Therapeutics), indicated for IgA nephropathy. Guide all efforts in preparation for the brand’s full label approval including omnichannel launch planning and campaign and messaging evolution.Led agency assignment for venglustat, Sanofi’s investigational therapy for late-onset Tay-Sachs and Sandhoff disease. Oversaw development of foundational strategy for pre-launch disease education and branded campaign launch. Included insight mining, audience identification and persona development, creation of unbranded and branded narratives/message houses, omnichannel engagement framework design, and promotional campaign development for branded launch.Oversaw all consumer work for FABHALTA (Novartis), a novel factor B inhibitor across three rare diseases – PNH, C3G and IgA nephropathy. Orchestrated and expedited into market a robust, cross-indication disease awareness campaign, inclusive of website, patient advocacy, social, digital, CRM and custom programs. Guided launch planning, positioning, messaging and campaign development in anticipation of brand’s expedited FDA approval. Built 10-person account team; responsible for $10M annual revenue.Responsible for the $65MM DTC launch of KESIMPTA (Novartis) in relapsing MS. Oversaw pre-launch planning, campaign development, and the overall omnichannel effort for the brand’s first two years in market. Championed Novartis’ first-ever dynamic content optimization initiative resulting in a 25% lift in digital ad performance. First year in market, DTC campaign exceeded Novartis launch benchmarks across all key measures. Oversaw 9-person account team; responsible for $9.5M annual revenue.

Northwestern University - Kellogg School of Management

Master of Business Administration (MBA)

Duke University

Bachelor of Arts (B.A.)